Newsroom | 1552 results
Sorted by: Latest
-
Gilead Sciences Announces First Quarter 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our base business grew 4% year-over-year, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus...
-
The Pandemic Agreement Finalized, but Falls Short, says AHF
MEXICO CITY & MIAMI & SÃO PAULO--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute acknowledge the conclusion of three years of negotiations on the global pandemic agreement text by congratulating the negotiators—particularly representatives of the Equity and Africa Groups—and recognizing the contributions of key stakeholders, including civil society, who championed equitable access to public health goods. “Even before the COVID-19 pandemic, we beg...
-
Soleo Health Selected as Exclusive In-Network Specialty Pharmacy for Qfitlia™ a Treatment Option for Adults With Hemophilia A and B With and Without Inhibitors
FRISCO, Texas--(BUSINESS WIRE)--SOLEO HEALTH SELECTED AS EXCLUSIVE IN-NETWORK SPECIALTY PHARMACY FOR QFITLIA™ TREATMENT OPTION FOR ADULTS WITH HEMOPHILIA A&B WITH/WITHOUT INHIBITORS...
-
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will participate in a Fireside Chat at 1:40 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approx...
-
AHF desmiente información falsa sobre el SIDA y la transmisión del VIH por alimentos
Ciudad de México--(BUSINESS WIRE)--En los últimos días, comenzó a circular en redes sociales y plataformas de mensajería instantánea una cadena que asegura que un niño de 10 años contrajo VIH en Barbados tras comer piña contaminada con sangre. A raíz de este mensaje, que se ha viralizado en varios países de América Latina y el Caribe, AHF América y El Caribe considera necesario aclarar públicamente que esta información es falsa y carece por completo de base científica. Desde AIDS Healthcare Fou...
-
AHF Refutes Misinformation About AIDS and Food Transmission
MEXICO CITY--(BUSINESS WIRE)--In recent days, a message has been circulating on social media and messaging platforms claiming that a 10-year-old boy in Barbados contracted HIV after eating pineapple contaminated with blood. In response to this message, which has gone viral in several countries across Latin America and the Caribbean, AHF Latin America & Caribbean finds it necessary to publicly clarify that this information is false and entirely lacking in scientific basis. AIDS Healthcare Fo...
-
New Robert Vargas Mural Honors Fight Against Hunger
LOS ANGELES--(BUSINESS WIRE)--New Robert Vargas Mural Honors Fight Against Hunger...
-
Novotech Report Reveals Global Surge in Infectious Disease Trials as Industry Nears 2,000 Studies Since 2020
SYDNEY--(BUSINESS WIRE)--Novotech Report Reveals Global Surge in Infectious Disease Trials as Industry Nears 2,000 Studies Since 2020...
-
Novotech報告揭示:自2020年以來,傳染病臨床試驗全球激增,業界研究接近2000項
雪梨--(BUSINESS WIRE)--(美國商業資訊)-- Novotech作為一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司,致力於攜手生物科技公司以及中小型製藥公司,共同推動藥物開發。近日,Novotech發佈了一份新報告,分析了不斷變化的傳染病臨床試驗領域。本報告為2025年在全球傳染病研發領域的複雜環境中摸索前行的製藥和生物科技公司提供了關鍵策略洞察。 探索傳染病臨床試驗的未來 2020年至2024年間,全球傳染病臨床試驗顯著成長,已經啟動、展開或規劃的臨床試驗近2000項。在政府的大力支持和國際合作的推動下,亞太地區在這一擴張趨勢中佔據重要地位,年複合成長率 (CAGR) 高達70%。其次是北美地區,CAGR達到52%,主要得益於生物科技領域巨額投資的持續湧入。歐洲及全球其他地區的臨床試驗則穩定成長,這種趨勢不僅促進了全球臨床研究的地域多樣性,也增強了臨床試驗體系的穩健性。 主要發現: 全球臨床試驗成長:在全球傳染病臨床試驗版圖中,亞太地區占有比例較高,達43%,其次是北美 (21%)、歐洲 (20%) 以及世界其他地區 (16%)。 重點治療領域:...
-
诺为泰报告揭示:自2020年以来,传染病临床试验全球激增,行业研究接近2000项
悉尼--(BUSINESS WIRE)--(美国商业资讯)-- Novotech(诺为泰)作为一家可提供全方位服务的国际性临床研究组织 (CRO) 和科学咨询公司,致力于携手生物科技公司以及中小型制药公司,共同推进药物开发。近日,诺为泰发布了一份新报告,分析了不断演变的传染病临床试验格局。本报告为2025年在全球传染病研发领域的复杂环境中摸索前行的制药和生物科技公司提供了关键战略洞察。 探索传染病临床试验的未来 2020年至2024年间,全球传染病临床试验显著增长,已经启动、开展或规划的临床试验近2000项。在政府的大力支持和国际合作的推动下,亚太地区在这一扩张趋势中占据重要地位,复合年增长率 (CAGR) 高达70%。其次是北美地区,CAGR达到52%,主要得益于生物科技领域巨额投资的持续涌入。欧洲及全球其他地区的临床试验稳步推进,这种趋势不仅促进了全球临床研究的地域多样性,也增强了临床试验体系的稳健性。 主要发现: 全球临床试验增长:在全球传染病临床试验版图中,亚太地区占比较高,达43%,其次是北美 (21%)、欧洲 (20%) 以及世界其他地区 (16%)。 重点治疗领域:传染病...